Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer
about
Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.A phase I trial and in vitro studies combining ABT-751 with carboplatin in previously treated non-small cell lung cancer patients.Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer.Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.Emerging antiangiogenic therapies for non-small-cell lung cancer.Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed?Indole molecules as inhibitors of tubulin polymerization: potential new anticancer agents.Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies.The place of pemetrexed in the management of non-small-cell lung cancer patients.New prospects for drug development: the hedgehog pathway revealed. Focus on hematologic malignancies.Tubulin inhibitors: a patent review.Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies.Early investigational tubulin inhibitors as novel cancer therapeutics.An update on the developing mitotic inhibitors for the treatment of non-small cell carcinoma.
P2860
Q26781365-2D2C6C6A-9306-4139-8888-9255E906BBF0Q33400716-60FAFBBD-DD64-4686-8541-BFA6B945C795Q33817062-E54F4E8E-FE32-4C6C-937A-AB9B4D48285FQ35964716-2A9A280E-2608-4937-834D-C951ACFDE4CEQ36605647-67F51935-CBB8-4193-872E-73549A4BE3D5Q36968457-EE16E5E0-900B-43C9-9BB0-3B16938274C0Q37382760-C9C06236-8BFE-48A7-BB2B-050710DAB4A9Q37945645-C338A2B3-084C-47B3-A805-B5F243BBF479Q38000486-033601B6-51B5-4D28-B2E8-829CA5F0D13EQ38060185-94627CF3-9550-49EB-8732-2CA7BB511684Q38062018-CD4A2FFD-62F8-403A-9D89-ED50C664F8A9Q38087999-5303B051-FBD0-40C1-B14D-5640D1778D09Q38104413-C8B078E2-DEE6-4068-8EC8-B3A997EDF5C4Q38169237-C8009EF4-F5A2-4BA5-9256-604094DFC327Q38194590-7918ACFC-3106-4ED4-A962-24B1FC899D16Q38836161-E44AC484-B747-44CF-A490-AC6838ABB7A0Q47553028-AA7FE868-0E93-4BF6-9964-D5E21230120F
P2860
Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Phase I/II study of pemetrexed ...... tic non-small-cell lung cancer
@ast
Phase I/II study of pemetrexed ...... tic non-small-cell lung cancer
@en
type
label
Phase I/II study of pemetrexed ...... tic non-small-cell lung cancer
@ast
Phase I/II study of pemetrexed ...... tic non-small-cell lung cancer
@en
prefLabel
Phase I/II study of pemetrexed ...... tic non-small-cell lung cancer
@ast
Phase I/II study of pemetrexed ...... tic non-small-cell lung cancer
@en
P2093
P2860
P356
P1476
Phase I/II study of pemetrexed ...... tic non-small-cell lung cancer
@en
P2093
Andrew Coates
Andrew Krivoshik
Barry Dowell
Evelyn McKeegan
Gary Gordon
Michael Wertheim
Peter Ansell
Rajendra Pradhan
P2860
P304
P356
10.1200/JCO.2010.32.5944
P407
P577
2011-02-07T00:00:00Z